Search results
Showing 1126 to 1140 of 2005 results for nice guidelines
Summary of the evidence on remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn’s disease and ulcerative colitis
Evidence-based recommendations on liraglutide (Saxenda) for managing overweight and obesity alongside a reduced-calorie diet and increased physical activity in adults.
Ranibizumab and pegaptanib for the treatment of age-related macular degeneration (TA155)
Evidence-based recommendations on ranibizumab (Lucentis) and pegaptanib (Macugen) for treating wet age-related macular degeneration in adults.
Evidence-based recommendations on pembrolizumab (Keytruda) with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma in adults.
This manual explains how NICE develops and updates social care guidance. It provides advice on the technical aspects of guidance development and the methods used
Evidence-based recommendations on tirzepatide (Mounjaro) for type 2 diabetes in adults.
Four commonly used methods to increase physical activity (PH2)
This guideline covered four common methods used to increase the population's physical activity levels: brief interventions in primary care, exercise referral schemes, pedometers and community-based walking and cycling programmes. It has been updated and replaced by the following NICE guidelines: Walking and cycling (2012) PH41 Physical activity: brief advice for adults in primary care (2013) PH44 Exercise referral schemes to promote physical activity (2014) PH54
applicable) Why this is important:- The evidence review for the NICE guideline on hearing loss found a lack of evidence to...
investigations before starting antipsychotic medicines recommended in the NICE guidelines on psychosis and schizophrenia in adults and...
with significant variation between different international and national guidelines. Current practice in the NHS is to give anti-D to all...
Evidence-based recommendations on rivaroxaban (Xarelto) for preventing atherothrombotic events in adults with coronary or peripheral artery disease.
Smoking: smoking status of people with bipolar, schizophrenia and other psychoses (IND154)
This indicator covers the percentage of patients with schizophrenia, bipolar affective disorder or other psychoses whose notes record smoking status in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM124
Evidence-based recommendations on Alpha-Stim AID for managing anxiety disorders.
Find out more about NICE technology appraisals advisory committee D members
Find out more about NICE technology appraisals advisory committee D members